Esophageal Squamous Cell Carcinoma

The study reveals that microplastics, as emerging pollutants, can enhance tumor cell proliferation and harm normal esophageal epithelium. These results suggest that NPs exhibit dual toxicological effects on tumor cells and normal esophageal epithelial cell models.

Moreover, as one of the model CRGs, the tumor-suppressive role of SULT1B1 in ESCC was experimentally verified in vitro. These results provide novel insights into enhancing the prognosis of ESCC and formulating treatment strategies.

The validated IBS model provides high-precision prediction of postoperative LNM risk in ESCC. It offers a novel framework ("tumor antigen burden-lymphangiogenesis-immune microenvironment") for improving patient risk stratification, guiding adjuvant therapy decisions (including immunotherapy response prediction), and optimizing resource allocation, thereby potentially impacting ESCC management paradigms.

Genipin targets TNK2 to inhibit the progression of ESCC. It provides new insights into the pathogenesis of ESCC and theoretical basis for positioning TNK2 gene as a potential therapeutic target.

Our findings establish that circ_0001741 drives ESCC progression by modulating the miR-194-5p/E2F3 axis, underscoring its therapeutic potential for ESCC treatment.

In addition to the quality guideline-compliant technical performance of the tests, the biological heterogeneity of many of these biomarkers is also a diagnostic and clinical challenge. The current article provides an overview of current biomarker testing in the context of current treatment options for cancer of the upper gastrointestinal tract.

ESCC patients with FAT1, FGF3, FGF12, and FGF19 mutations; advanced M stage; and high neutrophil counts tended to have poorer prognoses. A model based on a four-gene signature effectively predicts the prognosis of ESCC patients.

P2, N=48, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

Baseline and preoperative blood parameters (MPV, PDW, P-LCR) and preoperative ApoA1 are valuable predictors of treatment response and prognosis in LA-ESCC. Nomograms incorporating these markers offer reliable prognostic insights for DFS.

Selumetinib, entinostat, and erlotinib were identified as candidate drugs for cluster 2, whereas tozasertib, alpelisib, and cediranib showed higher suitability for cluster 1. Ten potential biomarkers, 13 transcription factors, and 2 miRNAs were characterized. This study elucidates the role of UPS in ESCC progression and provides a framework for personalized treatment strategies.

This disrupts GC reactions by competing with the CXCL12-CXCR4 signaling axis via MIF-CXCR4 interactions, thereby impairing B cell-mediated immunity. MIF+ tumor cells in GCs may be a biomarker for predicting immunotherapy resistance in ESCC.